An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.


Chandramohan, D; Hodgson, A; Coleman, P; Baiden, R; Asante, K; Awine, E; Owusu-Agyei, S; Boutriau, D; Nelson, CB; Greenwood, B; (2007) An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine. Vaccine, 25S1. A83-A91. ISSN 0264-410X DOI: 10.1016/j.vaccine.2007.04.047

Full text not available from this repository. (Request a copy)

Abstract

The immunogenicity and safety of a meningococcal trivalent A/C/W135 polysaccharide vaccine was compared with that of a tetravalent A/C/Y/W135 polysaccharide vaccine in a randomised, double blind trial. The study included 360 adults, who received either a trivalent or tetravalent polysaccharide meningococcal vaccine. Antibody responses were determined by serum bactericidal antibody (rSBA) assays prior to vaccination and on day 28 and month 11 after vaccination. The percentage of participants in the trivalent vaccine group who had rSBA titres >/=8 on day 28 post-vaccination against serogroups A, C and W135 meningococci were 99, 98 and 91%, respectively. The corresponding figures in the tetravalent vaccine group were 99, 99 and 90%. The percentage of participants with various cut off levels of rSBA against serogroups A, W135 and C meningococci on day 28 and 11-month post-vaccination and the incidence of adverse events did not differ significantly between the two groups.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Disease Control
Research Centre: Vaccine Centre
PubMed ID: 17521782
Web of Science ID: 249521900017
URI: http://researchonline.lshtm.ac.uk/id/eprint/9914

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
307Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item